ライフサイエンスコーパス: walk test

1 or an increase of >50 meters on the 6-minute walk test).

2 p differences were observed for the 6-minute walk test.

3 oxygen consumption measurement, and a 6-min walk test.

4 dynamics, functional class, and the 6-minute walk test.

5 lth questionnaires, and completed a 6-minute walk test.

6 and less distance walked during the 6-Minute Walk Test.

7 SS), 9-hole peg test (HPT) and timed 25-foot walk test.

8 eadmill test, Timed-Stands Test, and 50-Foot Walk Test.

9 eadmill test, Timed-Stands Test, and 50-Foot Walk Test.

10 oxygen consumption during a 10-meter shuttle walk test.

11 ise capacity (E), measured by the six-minute-walk test.

12 ated to female gender, heart rate, and prior walk test.

13 aturation to 88% or less during the 6-minute walk test.

14 diography, electrocardiography, and 6-minute walk test.

15 walking impairment questionnaire, and 6-min walk test.

16 ween neuropathy groups were observed for the walk test.

17 ks after surgery, measured with the 6-minute walk test.

18 as assessed for 2 years using timed 20-meter walk tests.

19 a wide range of performance on this extended walking test.

20 y Status Scale, 9-Hole Peg Test, and 25-Foot Walking Test.

21 ly reduced error rate in a horizontal ladder-walking test.

22 f Bederson, rolling cylinder and ladder rung walking tests.

23 ed greater relative improvement in the 6-min walk test (11.6 m greater, 95% CI: 10.4 to 12.8 m) and t

24 ormed better (mean [+/- SE]) on the 6-minute walk test (1507 +/- 16 vs 1349 +/- 16 ft; P<.001), mean

25 ) were identified that reported the 6-minute walk test (2 RCTs), incremental shuttle walk test (2 RCT

26 nute walk test (2 RCTs), incremental shuttle walk test (2 RCTs), or peak oxygen consumption (2 RCTs)

27 f 45; P = 0.006) and improvement in 6-minute-walk test (+20.6 m vs. -25.0 m; P = 0.017) at Day 84.

28 ted by increased distances during a 6-minute walk test (390 +/- 91 versus 422 +/- 86 m, P < .05) and

29 p, P=0.24) or in the results of the 6-minute walk test (397 m in the fusion group and 405 m in the de

30 capacity (47.5 m for the incremental shuttle walking test, 45-85 s for the endurance shuttle walking

31 ients underwent functional testing (6-minute walk test, 50-foot walk test, and repeated sit-to-stand

32 overy at 1 minute of rest (HRR1) after 6-min walk test (6MW test) and clinical worsening in patients

33 The primary endpoint was change in 6-min walk test (6MWT) distance at 6 weeks.

34 The 6-min walk test (6MWT) distance increased in all 7 subjects at

35 yperinflation, and post-rehabilitation 6-min walk test (6MWT) greater than 140 m were enrolled from 1

36 The 6-minute walk test (6MWT) independently predicts congestive heart

37 fat fraction and (1) H2 O T2 ), and 6-minute walk test (6MWT) measurements.

38 quantity of desaturation during a six-minute-walk test (6MWT) would add prognostic information to cha

39 rcise capacity was evaluated by the 6-minute walk test (6MWT).

40 exercise capacity as documented by 6-minute walk test (6MWT).

41 al assessment in this study was the 6-Minute Walk Test (6MWT).

42 and improve distance walked on the 6-minute walk test (6MWT).

43 Patients with LAM also performed a 6-minute walk test (6MWT).

44 art Failure Questionnaire [MLHFQ], and 6-min walk test [6MWT]) were performed at baseline and 30 days

45 ellar Functional System score, Timed 25-Foot Walk Test, 9-Hole Peg Test (9-HPT), Symbol Digit Modalit

46 knowledge of desaturation during a 6-minute walk test adds prognostic information for patients with

47 icipants, 378 (80.6%) completed the 6-minute walk test and 285 (70.1%) completed Kansas city cardiomy

48 e performed for the timed 8-foot (ie, 2.4 m) walk test and a repeated sit-to-stand test.

49 iuretic peptide and negatively with 6-minute walk test and cardiac index.

50 included exercise capacity assessed by 6-min walk test and peak VO(2), Borg dyspnea score, hemodynami

51 The patients also performed a 6-minute walk test and short-form 36-Item Health Survey questionn

52 different techniques, the 6-minute corridor walk test and the 9-minute self-powered treadmill test.

53 sociated with an improvement in the 6-minute walk test and the MLHFQ score, but neither improved exer

54 , blood test, echocardiography, and 6-minute walk test and were followed up for mortality until the e

55 tudy sites, 245 participants underwent 6-min walk tests and Mini-Mental State Examination (MMSE) at i

56 priori included resting heart rate and 6-min walk tests and/or ambulatory electrocardiographic result

57 They also performed a shuttle walking test and comprehensive lung function tests.

58 d normalized sensorimotor function in a grid-walking test and provided complete axonal protection ove

59 rmance at 6 months, assessed by the 6-minute walking test and the five times sit-to-stand test, and i

60 assessed using clinical scoring of the beam-walking test and video-kinematic analysis (CatWalk) at b

61 Association class and results of a 6-minute walk test) and in quality of life (according to the Minn

62 om 13% to 89% of patients completing a 6-min walk test) and in quality of life (mean values improved

63 chnique), cardiovascular endurance (6-minute walk test), and functional status (Fibromyalgia Impact Q

64 e ability to walk 450 to 550 m on a 6-minute walk test), and were receiving optimal standard therapy,

65 atient-reported outcome measures, a 6-minute walk test, and a health economic evaluation.

66 rk Heart Association functional class, 6-min walk test, and deterioration or death.

67 George's Respiratory Questionnaire, 6-minute walk test, and imaging.

68 , in exercise capacity as evaluated by 6-min walk test, and in quality of life.

69 capacity, respiratory muscle strength, 6-min walk test, and incremental symptom-limited maximal exerc

70 ase questionnaire (CRQ), incremental shuttle walk test, and induced sputum.

71 aphy, magnetic resonance imaging, a 6-minute walk test, and measurement of natriuretic peptides befor

72 arsal diameter, functional ability on a beam walk test, and microscopic assessment of joint inflammat

73 the 6-minute walk test, incremental shuttle walk test, and peak oxygen consumption between the testo

74 Respiratory parameters, 6-min walk test, and QOL were measured.

75 unit and hospital, distance on the 6-minute walk test, and quality of life.

76 York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive

77 ctional testing (6-minute walk test, 50-foot walk test, and repeated sit-to-stand test) at baseline/p

78 erformance Battery, timed up and go, a 6-min walk test, and single-leg stands.

79 ty of life questionnaire, six-minute (6-min) walk test, and sputum markers of inflammation during a 6

80 ulmonary function tests (PFTs), the 6-minute walk test, and St George Respiratory Questionnaire (SGRQ

81 through a physical examination, the 6-Minute Walk Test, and the Functional Independence Measure Mobil

82 n functional class, ejection fraction, 6-min walk test, and the Minnesota score or its equivalent as

83 with metrics derived from PFTs, the 6-minute walk test, and the SGRQ.

84 rk Heart Association functional class, 6-min walk test, and ventricular function.

85 Research Arm Test, Ten-Meter and Six-Minute Walk Tests, and the Stroke Impact Scale.

86 king test, 45-85 s for the endurance shuttle walking test, and 46-105 s for constant-load cycling end

87 t resting cardiovascular measurements, 6-min walking tests, and cardiopulmonary exercise testing.

88 esign of future DMD trials with the 6-minute walk test as the endpoint.

89 We developed a 30 m walking test as a quantifiable measure of severity of ce

90 atory fitness (as measured with the 6-minute walk test), assessed at baseline and at 3, 6, 9, 12, and

91 improvement of at least 54 m in the 6-minute walk test at 6 months (1-sided hypothesis test).

92 operative functional walking capacity (6-min walk test) at 4 weeks after surgery.

93 et of 1096 participants performed a 6-minute walk test before FMD determination.

94 h biopsy-proven disease performed a 6-minute walk test between January 1996 and December 2001.

95 as no significant difference in the 6-minute walk test between the inpatient rehabilitation and eithe

96 ificant motor improvement in the ladder rung walk test but not the forelimb reaching test.

97 ere was no between-group difference in 6-min walk test, but 15 IMT patients (compared with 9 placebo)

98 aged 50 years or older, underwent: 6-minute walk test (cardiopulmonary endurance), chair stands in 3

99 Patients were evaluated using the 6-min walk test, changes in NYHA functional class, cardiac fun

100 The 8-foot walk test compared subjects in the lowest and highest qu

101 pose of this study was to determine if 6-min walk test data assists in treatment decisions for patien

102 estionnaires, Timed-Stands Test, and 50-Foot Walk Test demonstrate that the HAP is a valid measure of

103 mic and metabolic assessment during 6-minute walk tests demonstrates that in patients with heart fail

104 The treadmill exercise time and the 6-min walk test did not change significantly after replacement

105 iuretic peptide concentrations, and 6-minute walking test did also not differ between groups.

106 e same pattern was observed for the 6-minute walk test distance (+125 +/- 33 m in the transendocardia

107 cirrhosis had poorer performance in 6-minute walk test distance (231 vs 338 m), 30-second chair stand

108 AP) more than or equal to 14 mm Hg and 6-min walk test distance (6-MWD) less than or equal to 300 m.

109 The effects on BODE index, 6-minute-walk test distance (6MWD), and health-related quality of

110 SD 9.8] to 79.1 [13.0]; p=0.0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318

111 prior hospitalizations (P < .0001), 6-minute walk test distance (P < .0001), CT RA950 relative area w

112 ore increased (mean: 43.1 to 77.0) and 6-min walk test distance results increased (mean: 163.6 to 252

113 eptide/B-type natriuretic peptide, the 6-min walk test distance, and health-related quality of life i

114 to treatment was assessed using the 6-minute walk test distance, which increased in 25 subjects and d

115 SFTPB (p = 0.005) were associated with 6-min walk test distance.

116 ation was stratified by country and by 6 min walk test distance.

117 d less postoperative improvement in 6-minute walking test distance (80+/-78 versus 42+/-41 m, P<0.000

118 as well as the lowest long jump and 6-minute walk test distances (P < .05).

119 Efficacy assessments included 6-minute walk test, exercise peak VO2, Minnesota Living with Hear

120 y Questionnaire (SGRQ), completed a 6-minute walk test for the 6-minute walk distance (6MWD), and und

121 was evaluated using the neuroscore and beam walk tests for 4 weeks postinjury (n = 11).

122 improvements in functional status and 6-min walk test (from 0% to 83% of patients in New York Heart

123 Extended walking tests have been examined as outcome predictors i

124 The 6-minute walk test improved more in depression remission compared

125 Six-min-walk-test improved 59.5 +/- 112.4 m, and Minnesota-livin

126 The distance covered during the 6-minute walking test improved in the exercise group (mean distan

127 onal class III/IV in 82.5%), frail (slow 5-m walk test in 81.6%), and have poor self-reported health

128 unctional assessment comprising the 6-minute walk test in ambulant individuals.

129 es were not significant, including the timed walking test in the off condition (p=0.053), the Purdue

130 tolerance: The distance covered over a 6 min walk test increased from 934 +/- 297 to 1,071 +/- 241 ft

131 The 6-min walk test increased with allo-hMSCs by 37.0 m (p = 0.04)

132 The mean increase in the 6-minute walk test, incremental shuttle walk test, and peak oxyge

133 s, poor performance on treadmill or extended walking tests indicates closer proximity to future healt

134 The 6-minute walk test is used in clinical practice and clinical tria

135 (using a modified Naughton protocol), 6-min walk test, left ventricular ejection fraction and dyspne

136 =80 beats/min; and maximum HR during a 6-min walk test </=110 beats/min or average HR during 24-h Hol

137 ndergoing TAVR included poor mobility (6-min walk test <50 m; hazard ratio: 1.67, p = 0.0009) and oxy

138 low exercise capacity were defined as 6-min walk test <50% predicted or use of rollator or wheelchai

139 d changes at 6 and 12 months in the 6-minute walk test, lung function, quality of life as assessed by

140 res, and 4990 (10.2%) completed the 6-minute walk test, made available only at the end of 7 days.

141 ving with Heart Failure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biom

142 w during maximal handgrip exercise, 6-minute walk test, maximal oxidative capacity, and life quality;

143 symptom limited maximum exercise test, 6-min walk test, maximal static inspiratory and expiratory mou

144 tus Scale, Nine Hole Peg Test, Timed 25-Foot Walk Test, Multiple Sclerosis Walking Scale-12, and Modi

145 Heart Association class III dyspnea or 6-min walk test of <330 m) at 6-month follow-up.

146 y volume in 1 second (FEV1) and the 6-minute walk test on intention-to-treat analysis.

147 There was no change in 6-min walk test or New York Heart Association functional class

148 ed Disability Status Scale (EDSS), 25' Timed-Walk Test, or Nine-Hole Peg Test to assess time to 3-mon

149 ressive symptoms (P=0.027), and the 6-minute walk test (P=0.012).

150 Questionnaire), functional status (6-minute walk test, peak maximum oxygen consumption), biomarker (

151 g With Heart Failure Questionnaire, 6-minute walk test, peak maximum oxygen consumption, N-terminal p

152 block method stratified by baseline 6-minute walk test performance.

153 (muscle and/or nerve function), and 6-minute-walk test (physical function).

154 Participants completed a 400-m walk test prior to bariatric surgery (n = 206) and at 6

155 ated with poorer performance in the 6-minute walk test (R=0.36, P=0.03).

156 4, p < 0.0001; Activity score versus shuttle walking test, r = -0.659, p < 0.0001; and impacts score

157 es also correlated with an improved 6-minute walk test result, although this correlation was weaker.

158 Six-minute walk test results and sputum analysis for cell count and

159 ssociated with improved NYHA class, 6-minute walk test results did not improve.

160 with saturation > 88% during their baseline walk test, serial decreases in FVC and increases in desa

161 The 6-min walk test (SMWT) performed in the hallway (HW) is used a

162 se-induced desaturation (during the 6-minute walk test, Spo2 >/=80% for >/=5 minutes and <90% for >/=

163 ), submaximal exercise performance (6-Minute Walk Test), standing balance (Functional Reach Test), sk

164 e indicates greater disability), and 25-Foot Walking Test (test covers 7.5 m; measured in seconds; lo

165 0.05) and shorter time to complete a narrow walk test than men who took part in only lifestyle physi

166 nd underwent echocardiography and a 6-minute walk test (the composite primary end point).

167 ly reduced muscle strength and a longer 10 m walk test time in young, ambulant patients with DMD; bot

168 provements were observed at 6 months for the walk test time to completion (mean, 376 seconds; 95% CI,

169 ults, we administered the standardized 6-min walk test to 117 healthy men and 173 healthy women, aged

170 ility Status Scale (EDSS), the timed 25-foot walk test (TWT), and the nine-hole peg test.

171 A 6-min walk test utilizing a treadmill (TM) is easier to perfor

172 postprocedural quality of life and 6-minute walk test were ascertained.

173 -Item Short-Form Health Survey, and 6-minute walk test were used to assess health status.

174 Six-min walk tests were conducted at baseline, 3 weeks, 4 months

175 invasive hemodynamic measurements and 6-min walk tests were performed and outcomes prospectively fol

176 An encouraged 6-minute walk test with metabolic measurements was used to assess

177 ht-sided heart catheterization, and 6-minute walk testing with a median follow-up of 4.0 years.

178 before and after iloprost inhalation, 6-min walk test, World Health Organization functional class, a

179 thesized that desaturation during a 6-minute walk test would predict mortality for patients with usua